NL
ZVRA icon

Navalign LLC’s Zevra Therapeutics ZVRA Stock Holding History

Navalign LLC’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50
Closed -$448 – 495
2025
Q4 		$448 Buy
+50
New +$473 ﹤0.01% 471

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Navalign LLC's ZVRA Position: Q1 2026 in Review

Navalign LLC sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 50 shares — an estimated $448 sold.

Navalign LLC first reported a position in ZVRA in Q4 2025 and held it in 1 quarter. The position peaked at $448 in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Navalign LLC reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Navalign LLC sold 50 Zevra Therapeutics shares in Q1 2026, an estimated $448.
  • Navalign LLC first reported a position in Zevra Therapeutics in Q4 2025 and held it in 1 quarter.
  • Navalign LLC's Zevra Therapeutics position peaked at $448 in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Navalign LLC's 13F filing for Q1 2026, filed 29 Apr 2026.